about
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesBiological interactions between herpesviruses and cyclooxygenase enzymesEpoxides and soluble epoxide hydrolase in cardiovascular physiologyMyeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Case-control study of aspirin use and risk of pancreatic cancer.Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirinRole of COX-2 in the bioactivation of methylenedianiline and in its proliferative effects in vascular smooth muscle cells.Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trialAbnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide.Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.Corticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-betaCox-2 Inhibition Protects against Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis via Akt-Dependent Enhancement of iNOS ExpressionCyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model.Aspirin reduces the prothrombotic activity of C-reactive protein.
P2860
Q24597172-E478A54B-4300-4634-A998-AE6C5FAFCC73Q28200565-6C44E576-3692-4C24-9AB8-B72B96F1AA23Q28396313-A5762057-6B4E-49CA-8606-BDD0ABDDD69CQ33607097-925708B9-46DD-4C96-B304-4014415127DBQ33640357-F67EA57D-562C-4AAE-9304-60540A82FFA2Q33881059-03904C51-99EA-498C-B5BC-10EBFE28213BQ33992761-A9BF8091-786F-4C93-883B-2B1318C101D3Q35511134-CC29F3CC-50DF-4DCA-98E5-54E7E3B4709DQ35789318-ABA91D8C-5847-4728-B0AF-B7B4691D96BEQ35850309-C14E211A-731F-4642-8446-051695C4607FQ35996689-88132B94-2755-4962-B863-A00753A56B7DQ36215333-F299879A-E001-4AAF-B596-24C16D6FC46AQ36955826-64267ABC-967F-4773-B7D2-2FF2AC06D045Q37344982-6D8F4444-6D7D-443C-B649-3BB4286A5882Q41884924-137402BD-D61E-48D0-A813-ACC8585DAC85Q45971278-7D655911-7870-4B09-944D-26E738A63606
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The cardiovascular pharmacology of COX-2 inhibition
@ast
The cardiovascular pharmacology of COX-2 inhibition
@en
The cardiovascular pharmacology of COX-2 inhibition
@nl
type
label
The cardiovascular pharmacology of COX-2 inhibition
@ast
The cardiovascular pharmacology of COX-2 inhibition
@en
The cardiovascular pharmacology of COX-2 inhibition
@nl
prefLabel
The cardiovascular pharmacology of COX-2 inhibition
@ast
The cardiovascular pharmacology of COX-2 inhibition
@en
The cardiovascular pharmacology of COX-2 inhibition
@nl
P3181
P1476
The cardiovascular pharmacology of COX-2 inhibition
@en
P2093
Susanne Fries
Tilo Grosser
P304
P3181
P356
10.1182/ASHEDUCATION-2005.1.445
P407
P577
2005-01-01T00:00:00Z